Atara Biotherapeutics

U-turn pivot about-face

Pharma

Atara, Pierre Fabre receive 2nd US rejection for Ebvallo

Atara didn't hold back in criticizing the FDA's rationale, noting that the regulator’s new point of view runs “contrary to the FDA’s prior guidance."

Fraiser Kansteiner Jan 12, 2026 11:30am

Conceptual illustration of layoffs featuring rows of translucent human figures overlaid with large blue scissors symbolizing

Fierce Biotech

Biopharma layoffs hit 4-year monthly high in May

Jul 8, 2025 2:26pm

Photo of a chain being held together by a piece of rope

Atara hit with cell therapy clinical hold after FDA inspection

Jan 21, 2025 9:59am

FDA

Atara, Pierre Fabre hit a hurdle with Ebvallo in the US

Jan 16, 2025 9:36am

Pierre Fabre

Pierre Fabre commits up to $640M in T-cell deal with Atara

Nov 3, 2023 11:04am

immune diseases

Off-the-shelf T-cell therapy wins world-first approval

Dec 19, 2022 3:22pm